Novavax (NVAX) Expected to Announce Earnings on Thursday

Novavax (NASDAQ:NVAX) will likely be announcing its earnings results before the market opens on Thursday, February 27th. Analysts expect the company to announce earnings of ($0.75) per share and revenue of $85.48 million for the quarter. Investors that are interested in participating in the company’s conference call can do so using this link.

Novavax Stock Performance

Shares of Novavax stock opened at $7.17 on Wednesday. Novavax has a 52-week low of $3.81 and a 52-week high of $23.86. The stock has a market capitalization of $1.15 billion, a price-to-earnings ratio of -3.17, a price-to-earnings-growth ratio of 2.85 and a beta of 2.14. The company has a fifty day moving average of $8.62 and a 200-day moving average of $10.07.

Analyst Ratings Changes

Separately, HC Wainwright reissued a “buy” rating and set a $19.00 price target on shares of Novavax in a research report on Tuesday, December 10th. One equities research analyst has rated the stock with a sell rating, two have given a hold rating and three have given a buy rating to the stock. According to data from MarketBeat.com, the company presently has an average rating of “Hold” and a consensus target price of $17.83.

Insider Buying and Selling

In other Novavax news, Director Rachel K. King sold 4,150 shares of the firm’s stock in a transaction dated Friday, December 13th. The shares were sold at an average price of $9.02, for a total transaction of $37,433.00. Following the completion of the sale, the director now directly owns 14,770 shares in the company, valued at approximately $133,225.40. This trade represents a 21.93 % decrease in their position. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which can be accessed through this hyperlink. Also, Director James F. Young sold 5,400 shares of the firm’s stock in a transaction dated Tuesday, December 31st. The shares were sold at an average price of $8.00, for a total transaction of $43,200.00. Following the sale, the director now owns 51,760 shares of the company’s stock, valued at approximately $414,080. This represents a 9.45 % decrease in their ownership of the stock. The disclosure for this sale can be found here. Insiders sold a total of 14,150 shares of company stock worth $119,641 in the last three months. 1.00% of the stock is owned by corporate insiders.

About Novavax

Novavax, Inc, a biotechnology company, that promotes improved health by discovering, developing, and commercializing vaccines to protect against serious infectious diseases. It offers vaccine platform that combines a recombinant protein approach, nanoparticle technology, and its patented Matrix-M adjuvant to enhance the immune response.